Abstract: An isolated and purified human nucleoprotein containing the amino acid sequence of SEQ ID NO:1; a polynucleotide encoding this protein; and an antibody against this protein. The above protein and antibody are useful in diagnosing and treating the pathogenic conditions of cancer, etc. The above polynucleotide is usable in acquiring the protein in a large amount. By screening a low-molecular weight compound binding to this protein, drugs of a novel type (antitumor agents, etc.) can be searched for.
Type:
Grant
Filed:
November 22, 2000
Date of Patent:
June 27, 2006
Assignee:
Japan Science and Technology Corporation
Abstract: Methods for the production of recombinant proteins containing repeating units are disclosed. Also disclosed are methods for the production of degenerate polynucleotides encoding said recombinant proteins. In addition, polypeptides and polynucleotides produced by the methods of current invention are also disclosed.
Type:
Grant
Filed:
March 13, 2001
Date of Patent:
June 13, 2006
Assignee:
Monsanto Technology LLC
Inventors:
Qi Wang, Zhonghon Guan, Brendan O. Baggot, Kristen Hadfield, Jianmin Zhao, Janice Edwards
Abstract: The present invention relates to the field of biotechnology. The invention provides a novel approach using tobacco mosaic virus omega leader sequence to enhance the solubility of the recombinant products in E. coli and the method of use therefore. The invention provides the utilization of tobacco mosaic virus omega leader sequence into E. coli expression vector, and the tobacco mosaic virus omega leader sequence containing expression vector can be used in combination with other available means to obtain higher expression or better solubility. The invention can be applied to biotechnological pharmaceutical industry, genetic engineering, biochemistry and molecular biology etc. The invention provides an expression vector pTORG, which is a highly efficient GST fusion expression vector, and can significantly enhance the yield of biologically active recombinant products.
Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.
Type:
Grant
Filed:
November 15, 2000
Date of Patent:
May 23, 2006
Assignee:
Board of Trustees of Leland Stanford University
Inventors:
Russell N. Van Gelder, Mark E. Von Zastrow, Jack D. Barchas, James H. Eberwine
Abstract: Disclosed herein are compositions and method useful in screening a compound for its interaction and/or effect with a molecular target and/or cellular process.
Abstract: Screening methods for identifying substances that provide therapeutic value for various diseases associated with protein misfolding are provided. Genetic and chemical screening methods are provided using a yeast system. The methods of the invention provide a rapid and cost-effective method to screen for compounds that prevent protein misfolding and/or protein fibril formation and/or protein aggregation which includes numerous neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, Huntington's disease as well as non-neuronal diseases such as type 2 diabetes.
Type:
Grant
Filed:
February 15, 2002
Date of Patent:
May 16, 2006
Assignee:
The University of Chicago
Inventors:
Susan Lindquist, Sylvia Krobitsch, Tiago Fleming Outeiro
Abstract: The present invention relates to somatic cell gene transfer methods for mimicking one or more effects of a drug candidate compound. In one aspect, the methods mimic the effect of a drug candidate compound with potential to potentiate or suppress activity of a selected target molecule. In another aspect, the methods provide means of identifying a molecular target for the drug candidate compound. The present methods have a variety of uses including providing identified molecular targets for use in drug screens.
Abstract: The invention features an enhancer cassette having the formula [X-Y]n, wherein each X is independently a noradrenergic cell-specific enhancer derived from a DBH gene; Y is absent or is a mono or polynucleotide that has between one and thirty nucleotides; and n is an integer between three and twenty, inclusive.
Abstract: The present invention provides methods and compositions for producing high titer, wild-type-free preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include novel nucleic acids encoding AAV helper functions and AAV helper function vectors. The present invention also includes host cells transfected by the claimed nucleic acids, methods of using the claimed vectors, and rAAV virions produced by such methods.
Abstract: The present invention concerns a method for improving the stability of linear short DNA towards exonucleases in cell-free in vitro transcription/translation systems using lysates containing exonucleases or in cellular systems containing exonucleases, wherein the stability of the linear short DNA is improved by adding unspecific linear DNA.
Type:
Grant
Filed:
April 17, 2002
Date of Patent:
March 14, 2006
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Manfred Watzele, Thomas Hoffmann, Cordula Nemetz, Dieter Heindl, Thomas Metzler, Wolfgang Mutter
Abstract: The present invention provides methods and composition for accessing, in a generally unbaised manner, a diverse genetic pool for genes involved in biosynthetic pathways. The invention also provides compounds which can be identified by cloning biosynthetic pathways.
Type:
Grant
Filed:
June 8, 2001
Date of Patent:
March 7, 2006
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Jo Handelsman, Robert M. Goodman, Michelle R. Rondon
Abstract: The invention relates to a method for the stabilization, purification or/and isolation of nucleic acids from material samples, in particular, stool samples, which can contain impurities and inhibitors or interfering substances. The invention further relates to a reagent kit for carrying out said method. The basis of the invention is, in particular, a method for purification, stabilization or/and isolation of nucleic acids from material samples, whereby a buffer is added to the sample containing the nucleic acids, with a pH value of 2 to 7, a salt concentration of at least 100 mM, or/and a phenol neutralizing substance. According to the invention, pure nucleic acids which may be amplified can be obtained from faecal samples by a simple method, which are suitable for diagnostic proof of infections, in particular, bacterial or viral infections, or mutations, in particular, for tumour-specific DNA mutations.
Abstract: The invention provides a novel gene, gridlock, and its encoded protein. gridlock plays a role in vascular development and modeling, and a mutation in gridlock has been associated with an aortic arch disease, coarctation. Thus, gridlock nucleic acid molecules and polypeptides can be used in methods of diagnosing, treating, and preventing gridlock-related diseases and conditions, such as aortic arch diseases.
Abstract: Disclosed herein are compositions and method useful in screening a compound for its interaction and/or effect with a molecular target and/or cellular process.
Abstract: Recombinant anaerobic bacterial compositions that under anaerobic conditions present in a solid tumor and produce an enzyme capable of catalyzing the conversion of a prodrug to its cytotoxic product in situ are described. Methods of treating tumors using the composition are also described.
Type:
Grant
Filed:
May 31, 2002
Date of Patent:
January 10, 2006
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
John M. Brown, Shie-Chau Liu, Amato J. Giaccia, Nigel P. Minton
Abstract: The present invention provides a method for identifying a gene which is expressed at a modulated level in an aggressive cancer by: (a) measuring baseline expression levels of genes in cancer cells; (b) introducing into the cancer cells an expression vector which directs expression of rat PEG-3; (c) measuring the expression levels of genes in the cells from step (b); and (d) identifying genes, the expression of which is modulated in an aggressive cancer. In another aspect of this invention, the measurement of expression levels of genes in step (a) and/or step (c) comprises measuring mRNA levels. In yet another aspect of the invention, the measurement of expression levels of genes in step (a) and/or step (c) comprises measuring RNA levels. In another aspect of the invention, the genes identified in step (d) are used for diagnosing whether a subject suffers from an aggressive form of cancer.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
January 3, 2006
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis, for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.
Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.
Type:
Grant
Filed:
July 8, 2003
Date of Patent:
October 25, 2005
Inventors:
Francis J. Martin, Samuel Zalipsky, Shi Kun Huang
Abstract: The present invention provides nucleic acid and amino acid sequences of acetyl CoA synthetase (ACS), plastidic pyruvate dehydrogenase (pPDH), ATP citrate lyase (ACL), Arabidopsis pyruvate decarboxylase (PDC), and Arabidopsis aldehyde dehydrogenase (ALDH), specifically ALDH-2 and ALDH-4. The present invention also provides a recombinant vector comprising a nucleic acid sequence encoding one of the aforementioned enzymes, an antisense sequence thereto or a ribozyme therefor, a cell transformed with such a vector, antibodies to the enzymes, a plant cell, a plant tissue, a plant organ or a plant in which the level of an enzyme has been altered, and a method of producing such a plant cell, plant tissue, plant organ or plant. Desirably, alteration of the level of enzyme results in an alteration of the level of acetyl CoA in the plant cell, plant tissue, plant organ or plant.
Type:
Grant
Filed:
November 13, 2002
Date of Patent:
September 13, 2005
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Basil J. Nikolau, Eve S. Wurtele, David J. Oliver, Robert Behal, Patrick S. Schnable, Jinshan Ke, Jerry L. Johnson, Carolyn C. Allred, Beth Fatland, Isabelle Lutziger, Tsui-Jung Wen